



To Determine the Frequency of Successful Outcome of Multi-Drug Resistant Tuberculosis Treated as Outpatient in a Tertiary Care Center

Naveed Pervez¹, Zia Ul Haq², Imtiaz Khan³ and Muhammad Umar^{4*}

¹ Department of Pulmonology, Lady Reading Hospital Peshawar, Pakistan

² Department of Pulmonology, Gajju Khan Medical College Swabi, Pakistan

³ Gajju Khan Medical College Swabi, Pakistan

⁴ Department of Pulmonology, Lady Reading Hospital Peshawar, Pakistan

*Corresponding e-mail: drumar98@gmail.com

ABSTRACT

Objectives: To determine the frequency of successful outcome of multidrug-resistant tuberculosis treated as outpatient in a tertiary care center. **Subject and methods:** This was a descriptive cross-sectional study done from 13 April, 2018 to 13 Oct, 2018. All the patients fulfilling inclusion criteria having age 20-60 years of either gender under treatment of MDR-TB for more than six months were enrolled in study the from Programmatic Management of Drug Resistance Tuberculosis (PMDT) site at Department of Pulmonology. Informed consent was taken from patients. Strictly exclusion criteria i.e. patients having neurological or psychological problems before diagnoses of MDR-TB (as per medical record in history), co-infection with HIV, was followed to exclude potential confounder and biases. Education status was evaluated and the response of treatment was checked in matriculate & under matric patients, also socioeconomic status was evaluated by asking about monthly salary whether below or above 12000, and subsequently their effect on treatment outcome. HIV screening is done through ICT method and DST for tuberculosis done on sputum of the patients in the Provincial Reference Lab in Hayat Abad Medical Complex Peshawar for diagnosis. **Results:** A total of 151 patients were included in this study, among which males were 94, and females were 57. The mean age was 41 years and S.D 10.82. As per the results, 110 (72.84%) patients were having a successful outcome. **Conclusion:** This study concludes that the out-patient treatment strategy success rate was 72.84% and it is feasible and safe for the treatment of MDR-TB patients.

Keywords: Tuberculosis (TB), Programmatic management of drug resistance tuberculosis (PMDT), Multidrug-resistant (MDR) strains

INTRODUCTION

Tuberculosis (TB) remains one of the biggest health problems in developing and industrialized countries and is associated with high rates of morbidity and mortality. The emergence and spread of *Mycobacterium tuberculosis* strains resistant to multiple drugs represent a serious threat to TB control worldwide [1]. The estimated prevalence of MDR among new cases was 1.8% and 6.7% among previously treated cases. The estimated number of new MDR-TB cases annually was 8,000 [2]. Early diagnosis of active TB and the detection of multidrug-resistant (MDR) strains are essential to interrupt transmission [3]. Treatment adverse events, pill burden, the rigidity of DOT, psychosocial support, and interaction with health personnel pose major challenges to adherence for concomitant anti-TB and antiretroviral treatments [4,5].

Management of multidrug-resistant TB (MDR-TB) patients is highly challenging. Such patients are subject to long and potentially toxic treatments and may develop several different psychiatric illnesses such as anxiety and depressive disorders. A mental health assessment before MDR-TB treatment initiation

may assist in early diagnosis and better management of psychiatric illnesses in patients already having two stigmatizing and debilitating diseases [6]. A study shows 51 patients (96.2%) had pulmonary while 3 patients (5.6%) had extra-pulmonary TB. History of exposure to tuberculosis patients was found in 36 (67.9%) patients. Treatment regimen with 2nd line drugs was decided on an individual basis according to DST on sputum culture results. The mean duration of treatment was 18 months. A successful outcome was seen in 25 patients (47.2%), 25 patients (47.2%) were lost to follow up and defaulted while 3 (5.6%) patients remain smear-positive at the end of treatment [7]. The success rate was 89.2% in those who completed the treatment. Treatment of MDR-TB is resource-intensive and lasts for 24 months or more, requiring a combination of second-line drugs that are more expensive, less effective and more toxic than those used in standard first-line treatment regimens [8,9]. The cure including the response rate of MDR-TB without Human Immunodeficiency Virus (HIV) infection using individual tailored regimens was reported from 39% to 96% in initially hospitalized patients [10-14].

The study aims to obtain fresh data with newer drugs that are provided free of cost to the patients by the Government through PMDT (Programmatic Management of Drug-Resistant TB) centers, and are not available in the market. All tests are done free of cost. It will improve patient's compliance to medications and ultimately successful outcome as most patients previously lost follow-up as well as a treatment due to the high financial burden. That will benefit as patients will rely more on government health centers with better results. And ultimately control of the disease. Local data mostly is old while international data is having a small sample size due to low disease burden there and not representative of our population due to the difference in socioeconomic conditions and living standards [15-19].

MATERIAL AND METHODS

This Cross-sectional descriptive study conducted at the Department of Pulmonology, Lady Reading Hospital Peshawar from 13 April, 2018 to 13 October, 2018. The sample size was 151 by taking the Prevalence of successful outcome 89%, CI=95%, and margin of error 0.05 as determined by WHO Calculator [7]. Sampling Technique was non-probability, consecutive sampling.

Inclusion Criteria

Patients age 20-60 years of either gender undergo the treatment of MDR-TB for more than 6 months.

Exclusion Criteria

Patients previously having neurological or psychological problems before a diagnosis of MDR-TB (as per medical record and history)

Co-infection with HIV which was confirmed by ICT method for the screening of HIV

Data Collection Procedure

All the patients fulfilling inclusion criteria having age 20-60 years of either gender under treatment of MDR-TB for more than six months were enrolled in the study from Programmatic Management of Drug Resistance Tuberculosis (PMDT) site at the Department of Pulmonology. Informed consent was taken from patients. Strictly exclusion criteria i.e. patients having neurological or psychological problems before diagnoses of MDR-TB (as per medical record in history), co-infection with HIV, was followed to exclude potential confounder and biases. Education status was evaluated and response of treatment was checked in matriculate & under matric patients, also socioeconomic status was evaluated whether below the poverty line or above by asking about monthly salary whether below or above 12000, subsequently their effect on treatment outcome. Screening for HIV was done through ICT method and DST for tuberculosis done on sputum of the patients in Provincial Reference Lab in Hayatabad Medical Complex Peshawar for diagnosis.

Data Analysis Procedure

All the collected data were entered into SPSS version 20 and analyzed through it. Quantitative data like age, salary, and duration of MDR-TB were presented as mean and standard deviation. Qualitative data like gender, salary categories, education level, and successful outcome was presented as frequency and percentage. Chi-square test was applied for the distribution of a dependent variable (the successful outcome of TB) with a different independent variable like gender, salary categories, education level. A successful outcome was stratified for age, gender, and duration of MDR-TB treatment to control effect modifier. The post-stratification analysis was done through the Chi-square test while keeping p-value ≤ 0.05 was taken as significant for the entire analytical test.

RESULTS

This study was carried out on 151 patients at the Department of Pulmonology, Lady Reading Hospital, Peshawar. Results are appended as per descriptive statistics, mean and SD for age was recorded as 41 years+10.82 and mean and SD for the duration of MDR-TB was recorded as 8 months + 0.56 (Table 1). Age-wise distribution, gender-wise distribution, socioeconomic status, and education level of patients recorded in Table 2, successful outcome recorded in Table 3. Stratification of a successful outcome with respect to age and gender are recorded in Tables 4 and 5.

Table 1 Descriptive statistics (N=151)

Quantitative Variables	Mean	SD
Age	41 Years	10.82
Duration of MDR-TB	8 Months	0.56

Table 2 Age and gender distribution, monthly income, an education level (N=151)

Age Group	20-40 Years	69	45.69%
	41-60 Years	82	54.30%
Gender	Male	94	62.25%
	Female	57	37.74%
Monthly Income	<Rs 12,000/-	59	39.07%
	>Rs 12,000/-	92	60.92%
Education Level	Non-Matric	55	36.42%
	Matric	96	63.57%

Table 3 Frequency and percentages for a successful outcome (N=151)

Successful Outcome	Frequency	Percentage (%)
Yes	110	72.84%
No	41	27.15%
Total	151	100%

Table 4 Stratification of a successful outcome with age (N=151)

Age	Successful Outcome	Frequency	Percentage (%)	p-value
20-40 Years	Yes	61	40.39%	0.0909
	No	8	5.29%	
41-60 Years	Yes	49	32.45%	
	No	33	21.85%	

Table 5 Stratification of a successful outcome with gender (N=151)

Gender	Successful Outcome	Frequency	Percentage (%)	p-value
Male	Yes	76	50.33%	0.68
	No	18	11.92%	
Female	Yes	34	22.51%	
	No	23	15.23%	

DISCUSSION

It is estimated 390000-510000 cases of MDRTB emerged globally (best estimate, 440 000 cases) [20]. Pakistan ranks eighth among the list of 22 high TB burden countries with a TB related death rate of 43/100,000 population annually [21]. The growth of the drug-resistant TB epidemic in Pakistan is presented as challenges for the National Tuberculosis treatment Plan (NTP). In a developing country like Pakistan inpatients treatment for MDR TB is not possible because of low resources and prolonged treatment duration and thus out-patient and Community-based treatment strategies have come into existence. Community-based treatment for drug-resistant TB has successful outcomes and has been reported elsewhere in the world [17]. There have been certain public-private partnerships and non-governmental organizations that have developed community-based treatment projects in parts of Southern Africa [22,23]. The main opinion in favor of in-patient treatment for drug-resistant TB relates to the need to administer and monitor complex, toxic drug regimens and to limit the community spread of drug-resistant TB. However, there is no proof that hospitalization actually limits community transmission and most patients have likely been infectious for several months before hospitalization [12]. Moreover, the risk of hospital-acquired infection transmission, both to other patients and health care workers, is also high [14,15]. More importantly, there are also economic and social costs involved in keeping patients isolated in hospitals, often away from their residence, and this can lead to default from treatment programs. 16 and therefore there is a salient need to build up a community-based strategy for the treatment of drug-resistant TB patients [24]. In our study as per the successful outcome, 110 (72.84%) patients were having a successful outcome (Table 3). These results support the evidence that it is feasible to develop a community-based treatment program for the patients who had MDR- TB. The major drawback of this strategy found to be is the high defaulter rate although we could not identify the exact cause of the defaulters was not known but most likely is the lack of education and cost of medications are the major hindrance. If the above two major hurdles are overcome then these MDR-TB patients can be safely managed within the existing infrastructure of the TB program where the expertise is available on an out-patient basis. Regarding the side effects, 52.8% developed some side effects due to medications but all are mainly minor, they did not require to discontinue the therapy and are managed accordingly as out-patient. This again favors that hospitalization is not usually necessary for the management of the side effects [25]. One interesting finding of our study is the presence of a high resistance pattern of other first-line drugs including Pyrazinamide (77.4%), Ethambutol (73.6%), and Streptomycin (69.4%). This is likely because the majority of our patients had got secondary MDR TB (90.6%) in which around one third (69.8%) had been treated with antituberculous drugs multiple times which is a risk factor for developing MDR TB.

Management of multidrug-resistant TB (MDR-TB) patients already having psychiatric illnesses such as anxiety and depressive disorders or can develop due to treatment. A mental health assessment before MDR-TB treatment initiation may assist in early diagnosis and better management of psychiatric illnesses in patients already having two stigmatizing and debilitating diseases [6]. A study shows 51 patients (96.2%) had pulmonary while 3 patients (5.6%) had extra-pulmonary TB. History of exposure to tuberculosis patients was found in 36 (67.9%) patients. Treatment regimen with 2nd line drugs was decided on an individual basis according to DST on sputum culture results. The mean duration of treatment was

18 months. A successful outcome was seen in 25 patients (47.2%), 25 patients (47.2%) were lost to follow up and defaulted while 3 (5.6%) patients remain smear-positive at the end of treatment⁷ which as per successful outcome, 110 (72.84%) patients were having successful outcome (Table 3). The success rate was 89.2% in those who completed the treatment. Treatment of MDR-TB is resource-intensive and lasts for 24 months or more, requiring a combination of second-line drugs that are more expensive, less effective and more toxic than those used in standard first-line treatment regimens^{8,9} as per successful outcome, 110 (72.84%) patients were having successful outcome (Table 3). The cure including the response rate of MDR-TB without human immunodeficiency virus (HIV) infection using individual tailored regimens was reported from 39% to 96% in initially hospitalized patients [10-14].

CONCLUSION

This study concludes that the out-patient treatment strategy success rate was 72.84% and it is feasible and safe for the treatment of MDR-TB patients.

DECLARATIONS

Conflicts of Interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

- [1] Moure, Raquel, et al. "Rapid detection of *Mycobacterium tuberculosis* complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method." *Journal of Clinical Microbiology*, Vol. 49, No. 3, 2011, pp. 1137-39.
- [2] Department of Health. "National tuberculosis management guidelines 2014." 2014.
- [3] Behr, M. A., et al. "Transmission of *Mycobacterium tuberculosis* from patient's smear-negative for acid-fast bacilli." *The Lancet*, Vol. 353, No. 9151, 1999, pp. 444-49.
- [4] Gebremariam, Mekdes K., Gunnar A. Bjune, and Jan C. Frich. "Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: A qualitative study." *BMC Public Health*, Vol. 10, No. 1, 2010, p. 651.
- [5] Toczek, A., et al. "Strategies for reducing treatment default in drug-resistant tuberculosis: Systematic review and meta-analysis." *The International Journal of Tuberculosis and Lung Disease*, Vol. 17, No. 3, 2013, pp. 299-307.
- [6] Das, Mrinalini, et al. "HIV, multidrug-resistant TB and depressive symptoms: When three conditions collide." *Global Health Action*, Vol. 7, No. 1, 2014, pp. 1-5.
- [7] Waheed, Zeeshan, et al. "Treatment outcome of multi-drug resistant tuberculosis treated as outpatient in a tertiary care center." *Pakistan Journal of Chest Medicine*, Vol. 17, No. 3, 2011, pp. 1-11.
- [8] World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. http://apps.who.int/iris/bitstream/10665/43965/1/9789241547581_eng.pdf
- [9] Nathanson, Eva, et al. "Multidrug-resistant tuberculosis management in resource-limited settings." *Emerging Infectious Diseases*, Vol. 12, No. 9, 2006, pp. 1389-97.
- [10] Rao, Nisar Ahmed, Zeeshan Mahfooz, and Muhammad Irfan. "Treatment outcome of multi-drug resistant tuberculosis in a tertiary care hospital in Karachi." *Journal of Pakistan Medical Association*, Vol. 59, No. 10, 2009, p. 694.
- [11] Goble, Marian, et al. "Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin." *New England Journal of Medicine*, Vol. 328, No. 8, 1993, pp. 527-32.

-
- [12] Flament-Saillour, Marie, et al. "Outcome of multi-drug-resistant tuberculosis in France: A nationwide case-control study." *American Journal of Respiratory and Critical Care Medicine*, Vol. 160, No. 2, 1999, pp. 587-93.
- [13] Telzak, Edward E., et al. "Multidrug-resistant tuberculosis in patients without HIV infection." *New England Journal of Medicine*, Vol. 333, No. 14, 1995, pp. 907-12.
- [14] Yagui M, Perales MT, Asenclos L. "Timely diagnosis of MDR TB under programme conditions is rapid susceptibility testing sufficient." *International Journal of Tuberculosis and Lung Disease*, Vol. 10, 2012, pp. 838-43.
- [15] Heller, T., et al. "Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa." *The International Journal of Tuberculosis and Lung Disease*, Vol. 14, No. 4, 2010, pp. 420-26.
- [16] Andrews, Jason R., et al. "Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa." *The Journal of Infectious Diseases*, Vol. 198, No. 11, 2008, pp. 1582-89.
- [17] Escombe, A. Roderick, et al. "The infectiousness of tuberculosis patients coinfecting with HIV." *PLoS Medicine*, Vol. 5, No. 9, 2008, p. 188.
- [18] Baleta, Adele. "Forced isolation of tuberculosis patients in South Africa." *The Lancet Infectious Diseases*, Vol. 7, No. 12, 2007, pp. 771-75.
- [19] Rep, MMWR Recomm, American Thoracic Society, and Infectious Diseases Society of America. "Treatment of tuberculosis." 2003, pp. 1-77.
- [20] Swaminathan, Soumya, et al. "Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: A randomized clinical trial." *American Journal of Respiratory and Critical Care Medicine*, Vol. 181, No. 7, 2010, pp. 743-51.
- [21] Centers for disease control and prevention. "Managing drug interactions in the treatment of HIV-related tuberculosis. CDC." 2008.
- [22] Abdool Karim, Salim S., et al. "Timing of initiation of antiretroviral drugs during tuberculosis therapy." *New England Journal of Medicine*, Vol. 362, No. 8, 2010, pp. 697-706.
- [23] Torok, M. Estee, and Jeremy J. Farrar. "When to start antiretroviral therapy in HIV-associated tuberculosis." *New England Journal of Medicine*, Vol. 365, No. 16, pp. 1538-40.
- [24] Rep, MMWR Recomm, and Centers for Disease Control. "Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society." 2000, pp. 1-51.
- [25] Jereb, John A., et al. "Recommendations for use of an isoniazid-rifampentine regimen with direct observation to treat latent *Mycobacterium tuberculosis* infection." *MMWR*, Vol. 60, 2011, pp. 1650-53.